ClinicalTrials.Veeva

Menu
The trial is taking place at:
U

Universitatsklinikum Essen | Ruhrlandklinik - Zentrum fur Schlaf- und Telemedizin

Veeva-enabled site

A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy (PUPFISH)

Roche logo

Roche

Status and phase

Enrolling
Phase 2

Conditions

Muscular Atrophy, Spinal

Treatments

Drug: Risdiplam

Study type

Interventional

Funder types

Industry

Identifiers

NCT05808764
BN44619
2023-505602-42-00 (Registry Identifier)

Details and patient eligibility

About

This study will evaluate the pharmacokinetics (PK) and safety of risdiplam in participants with spinal muscular atrophy (SMA) under 20 days of age at first dose.

Enrollment

10 estimated patients

Sex

All

Ages

Under 19 days old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Male or female newborn infant aged <20 days at first dose
  • Newborn infants with genetic diagnosis of 5q-autosomal recessive SMA or newborn infants identified as positive for SMA via newborn screening or via prenatal testing.
  • Gestational age equal to or greater than 37 weeks
  • Receiving adequate nutrition and hydration at the time of screening
  • Adequately recovered from any acute illness at baseline and considered well enough to participate in the study
  • Parent/caregiver is willing to consider nasogastric, nasojejunal, or gastrostomy tube placement during the study to maintain safe hydration, nutrition, and treatment delivery, if recommended by the investigator.

Exclusion criteria

  • Presence of clinical symptoms or signs consistent with SMA Type 0
  • In the opinion of the investigator, inadequate venous or capillary blood access for the study procedures
  • Systolic blood pressure or diastolic blood pressure or heart rate abnormalities
  • Presence of clinically relevant electrocardiogram (ECG) abnormalities
  • The infant (or the person breastfeeding the infant) taking any of the following: any inhibitor of CYP3A4 taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing, any inducer of CYP3A4 taken within 4 weeks (or within 5 times the elimination half-life, whichever is longer prior to dosing, and/or use of any multidrug and toxin extrusion (MATE) substrates taken within 2 weeks (or within 5 times the elimination half-life, whichever is longer) prior to dosing
  • Concurrent or previous administration of nusinersen or onasemnogene abeparvovec
  • Clinically significant abnormalities in laboratory test

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

10 participants in 1 patient group

Risdiplam
Experimental group
Description:
Participants will receive risdiplam once daily for 28 days.
Treatment:
Drug: Risdiplam

Trial contacts and locations

7

Loading...

Central trial contact

Reference Study ID Number: BN44619 https://forpatients.roche.com/

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems